Microcarrier Market was valued at USD 1.9 billion in 2021, growing at a significant CAGR of 11.6% during the forecast period 2022-28. The increasing demand for cell-based vaccines and mammalian cells in the biopharmaceutical industry and research institutes, and availability of private and public funding on cell-based research and advancements in technology drives the growth of the market. However, high cost of cell biology research and limitations in the production density hinders the growth of the market over the forecasted period. Following the World Health Organization’s (WHO) declaration of the epidemic as a pandemic, a combination of big pharmaceutical corporations and small start-ups rushed to create treatments and vaccinations. Companies have increased their research and development efforts in order to create vaccinations and treatments to combat the virus. Vaccine-related research in pharmaceutical and biotechnological firms, research centres, and academic and research institutes is regarded critical, and operations and output have been largely unaffected. Both the availability of financing and the demand for cell culture supplies, particularly microcarrier products, are likely to expand as research scales up.